ASCO 2019

1:49
CAR T-cell therapy: how caregivers are affected
Surbhi Sidana
1:30
Educating the patient about CAR T-cell therapy
Surbhi Sidana
3:28
Updates from the ZUMA-8 trial: KTE-X19 for R/R CLL
Ian Flinn
1:45
Renal and cardiac involvement in amyloidosis
Surbhi Sidana
1:27
ECOG-E3A06: lenalidomide vs. observation alone in SMM
Sagar Lonial
2:19
ARROW: carfilzomib dosing in frail R/R multiple myeloma patients
Maria-Victoria Mateos
1:15
DARA + pom-dex for R/R multiple myeloma
Sagar Lonial
1:40
Iberdomide with dexamethasone for R/R multiple myeloma
Sagar Lonial
2:36
DUO trial: duvelisib for CLL/SLL
Ian Flinn
1:45
QoL in patients undergoing CAR T-cell therapy versus transplantation
Surbhi Sidana
4:59
COLUMBA: subcutaneous daratumumab vs. IV administration
Maria-Victoria Mateos
3:12
CAR-T for ALL: the impact of bridging therapy
Karlo Perica
1:30
MRD: venetoclax vs. BTK-inhibitors for CLL
Susan O’Brien
1:00
CAR-T for ALL: bridging options and choices
Karlo Perica
1:26
Resonate: Ibrutinib associated with favourable PFS and OS in CLL
Susan O’Brien
0:59
Characterizing bridging strategies for CAR T-cell therapy
Karlo Perica
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals